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The course of the disease is highly variable, but it is most typically characterised by a relapsing pattern of acute exacerbations followed by periods of remission [relapsingremitting MS (RRMS)]. However, in up to 50% of the patients, this pattern evolves into a progressive course in which the clinical conditions slowly deteriorate over a period of years [secondary progressive MS (SPMS)] 2 . Considering this, the economic consequences come predominantly from the early loss of work capacity due to the development of physical disability, the impact of fatigue, the requirements of repeated hospitalisations during disease exacerbations and the need for assistance in daily life activities 3, 4 . Disease-modifying therapies (DMTs) were introduced in clinical practice in 1990 to reduce the frequency of relapses, slow disease progression and diminish disability in patients with MS [5] [6] [7] [8] [9] [10] . However, treatment options are particularly limited once the patients reach the SPMS stage. Although DMTs increase the direct costs of the disease, these costs are also offset since the use of DMTs reduces the frequency of relapses, days of hospitalisation, use of symptomatic treatments and the time of rehabilitation, making the final impact on the cost of the disease to be favourable. The mean total lifetime cost per patient of MS in the US was estimated to be USD 2.5 million in 1994 11, 12 . Several publications have addressed the epidemiology and costs of MS throughout the world 4, [13] [14] [15] [16] [17] . Nonetheless, our current knowledge of MS epidemiology and economic burden comes from North American and European studies 15, 16, 18, 19 . Scant data have been published from Latin America (LA) and the Caribbean (SA) 15, [20] [21] [22] [23] [24] . Thus, it is important to quantify the costs of MS in LA to better understand the impact of the disease on national health systems in the region 16, 19, 21, 24, 25 . Considering this, the aim of the present study was to perform a systematic review (SR) of the health economic data of MS in LA, including costs of hospitalisation, pharmacy data and outpatient as well as inpatient costs.
METHODS

Search strategy and selection criteria
We conducted a systematic, non-restricted, language search from January 1990 to September 2011 using electronic databases included in the Cochrane CENTRAL and specialised registers of the Cochrane Multiple Sclerosis Group, MEDLINE, EMBASE and LILACS. Regional databases, generic and academic internet searches, meta-search engines and databases containing regional proceedings or congresses' annals and doctoral theses, were also looked up. We consulted web sites from the main regional medical societies, experts and associations related to the topic. An annotated search strategy for grey literature was included to retrieve information from relevant sources like regional Ministries of Health, Pan American Health Organization and reports from hospitals following the MOOSE guidelines and the PRISMA statement for the reporting of SRs and meta-analyses 26, 27 . Outcome measures included mean cost of treatment of relapses (steroids and hospitalisation), mean cost of DMTs (by drug) and mean cost of disease by stage stratification measured by the expanded disability status scale (EDSS). Other outcomes searched were mean cost of rehabilitation and health-related patient's quality of life (QoL) and proxy of the patient's QoL (caregiver reported QoL for the patients).
The authors of the selected articles were contacted to obtain missing or additional information when considered necessary. Types of studies included cohort studies, casecontrolled studies, cross-sectional studies and case-series; data considering the outcomes previously described should have been provided in these studies. Randomised, controlled and quasi-randomised, controlled trials were included if they provided cost data for analysis.
Screening and data abstraction
Two reviewers independently pre-screened the titles and abstracts of all identified citations, and potentially eligible studies were selected. Two reviewers independently assessed the abstract and the full-text versions of all potentially eligible articles to verify the inclusion criteria. Any discrepancies were resolved by consensus in both phases.
Data were abstracted using a previously piloted electronic chart.
Assessment of risk of bias
Two reviewers independently evaluated the quality of the methodology used in studies included in the SR. The risk of bias of observational studies was assessed by a modified checklist available in Strengthening the Reporting of Observational studies in Epidemiology and in the study conducted by Fowkes and Fulton 29 . We prepared a summary of risk of bias considering six criteria (methods for selecting study participants, methods for measuring exposure and outcome variables, methods to control confounding, design-specific sources of bias and comparability among groups, statistical methods and declaration of conflict of interest). Once again, disagreements were resolved by consensus. The assessment of risk of bias is included in Table 1 .
Analyses
Included studies were analysed and abstracted to perform the review. All the abstracted data were entered into a computer database, and data from the two reviewers were compared and reconciled. The data has been presented in Table 2 .
RESULTS
Nine hundred and thirty nine citations were identified. After reviewing the titles and abstracts, 830 references were excluded and 108 studies were considered eligible. From those 108 studies, 7 studies met the inclusion criteria after full-text review and were included for data extraction (Table 1) 30-36 . Information for the review was provided from three countries (Brazil, Argentina and Colombia). Main characteristics of included studies are shown in Tables 1 and 2. Only two studies were published as full texts 33, 34 and the other five studies were presented as abstracts in regional meetings [30] [31] [32] 35, 36 . The studies were heterogeneous in many aspects including objectives, outcomes and sources of information. The investigators used mainly patient records and/or health insurance chart reviews as their data sources. Some used a single data source, while others used a combination ( Table 2) .
The first study identified that addressed cost-effectiveness was conducted in Argentina by Gonorazky
33
. The study aimed to evaluate the cost/efficacy ratio of DMTs [interferon beta (IFNβ) and glatiramer acetate (GA)] in Argentina, in RRMS, and to compare this information with data from the USA and UK. The estimated yearly costs of treatment of RRMS (in 2004) were as follows: GA, USD 35,280; IFNβ1b, USD 31,548; IFNβ1a, USD 43,080 (44 mcg, three times a week) and IFNβ1a, USD 29,256 (30 mcg, once a week). When the cost efficacy ratio was compared with USA and UK, prices of IFN and GA in Argentina exceeded by 89% and 191%, respectively 33 . The source of pharmacy data was taken from the market and it possibly overestimated the cost of DMTs. Other healthcare or societal costs were not considered.
The three studies that addressed DMT use, direct costs and some adherence of MS patients were performed in Brazil 32, 35, 36 . Two studies determined the distribution of MS-specific treatments in the Brazilian Public Healthcare System and the public pharmaceutical expenditures in MS patients in Brazil during [2006] [2007] [2008] [2009] . Both studies used a longitudinal analysis of Brazilian MS pharmacy claims as reported in the Brazilian Ambulatory Information System Database, which included aggregate data from 27 Brazilian states, observed annually. These results are shown in Table 2 Bueno, Godoy and Suzuki 35 performed a cross-sectional study in Sao Paulo, Brazil to evaluate the medication used by MS patients, costs and the patient's adherence to DMT treatment using the database of the Ministry of Health, called Datasus. The study retrieved information from January to December 2007. The results showed that DMTs accounted for 12.9% of high cost medications supplied by the public sector in Brazil. An average of 34.4% of patients adhered to the DMT treatment during the study period; the treatment options in Sao Paulo were distributed as follows: 61% for IFNβ1a subcutaneous (SC) or intramuscular (IM), 21% for IFNβ1b and 19% for GA. Adherence to DMT was almost 37% for GA, 34% for IFNβ1a (IM/SC) and 32% for IFNβ1b. When considering the level of adherence, the annual cost per patient treated was USD 27,824 for GA, USD 42,151 for IFNβ (SC/IM) and USD 34,038 for IFNβ1b. The total treatment cost estimated for that year was USD 92 million.
In another study, Ferreira da Silva et al. 36 performed a cross-sectional study in Sao Paulo, Brazil that focused on coverage of DMT treatment in MS patients. It was reported that the number of patients on DMT treatment in 2009 in the Sao Paulo region was 1319 patients, resulting in a prevalence of 11.9 cases per 100,000 inhabitants of RRMS patients. Considering this population, the cost for 2009 for the city of Sao Paulo was USD 23 million.
Another Brazilian study performed by Takemoto, Takemoto and Fernandes 32 aimed to determine the utilisation of health resources among MS patients in the public healthcare system. The analysis considered diagnosis of admission to the hospital, length of hospitalisation, mean length of stay (in days) in the intensive care unit, in-hospital mortality and mean cost per hospitalisation of MS patients. A comprehensive cost-study between 2003 and 2008, from a third party payer's perspective and including MS patients from three MS centres in the country, was conducted by Romero et al. 34 in Colombia. The study estimated direct and indirect costs according to the states of the disease (remissions and relapses,) and level of progression of the disease (EDSS) 37 . The disease was segmented into four categories according to EDSS (category 1: EDSS 0 to 2.5, category 2: EDSS 3 to 5.5, category 3: EDSS of 6 to 7.5 and category 4: EDSS 8 to 9.5) and the costs pertaining to each category were calculated. The study showed that the mean annual cost per patient varied across disease categories, with the highest cost in category 2 (USD 25,713) and the lowest cost in category 4 (USD 10,543). The cost of DMTs represented 91.5% of the mean total annual cost of categories 1, 2 and 3. Fifty-eight percentage of the population was treated with DMTs. Indirect costs were minimal, except for category 4, where increases in costs of DMT were offset by reduced usage of DMTs. This is the only identified study which estimated the direct and some of the indirect costs and clearly showed how costs increase with progression of the disease. All the results are shown in Table 2 . 
DISCUSSION
This review allowed us to characterise the research regarding the economics of MS and its treatments in LA. Despite the fact that the methodology for SR of noninterventional research is still in its early stages, valuable information may be extracted from the publications of MS costs in LA 15 . In our SR, performed with data obtained from the last 20 years, we found 7 studies meeting our objectives of addressing costs in the region (Tables 1 and 2 ). Despite the heterogeneity of studies identified, they provide several findings. Relapses are the main cause of admission in MS patients. The mean length of hospitalisation in admitted patients was 8.5 days and the expenditure involved in the admission of MS patients corresponded to 0.53% of the pharmaceutical expenditure in Brazil. In SA, the cost of hospitalisation seems to be low; we only retrieved an abstract on that data, but no full text was found to confirm this information. This shows a paucity of research in this area. More studies with better quality are needed in order to assess hospitalisations in the MS population. Additionally, no information was retrieved on rehabilitation. Other relevant information obtained relates to the total number of MS patients treated in some areas of Brazil as well as the cost of the specific DMT treatments in Brazil and Argentina. Only one study performed in Argentina suggests that the costs in LA for DMTs appear to be high compared with North America and UK, however, due to the limitations of the design and the data source used to obtain costs in the study, it is difficult to analyse this data 33 . It is also noteworthy that most studies assessing the costs of chronic disabling diseases had clear limitations; hence, the results could not be extrapolated to other latitudes. Finally, a study described both the direct and indirect costs of MS according to the disability of patients, measured by EDSS, in Colombia (Table 2) . This was the only study attempting to calculate indirect costs associated with MS and reporting the increased cost associated with advanced stages of MS patients. Additional studies should be conducted to estimate the indirect costs in such patient population.
Previous studies dealing with costs of MS in developed countries demonstrated that the costs of MS are substantial 4, 13 . Depending on the perspective taken and the severity of the disease, the cost of MS ranged from USD 6,511 to USD 77,938 per patient per year, in these developed regions 13 . However, this information could not be extrapolated to other regions where costs clearly have variations across countries, due to differences in their approach to data collection, the type of resources included, the assessment of resources, the type of patients involved, the sampling process and the quality of analysis. In addition, costs drivers varied across geographies probably due to the significant differences in the availability of services and use of resources across countries.
European studies demonstrated that with advancement of the disease, the increase of the economic burden was accompanied by changes in the distribution of costs. Thus, costs associated with DMT dominated the overall costs in lower disease-severity levels, while direct nonmedical and indirect costs, such as productivity losses, increased significantly with disease progression [38] [39] [40] . This study represents the first SR of MS costs in LA. Most of the evidence is limited to abstracts; only two full texts addressed this topic. Studies have been performed only in three countries of this region. Most of the research has been conducted in Brazil, focusing on different aspects of costs and benefits. The most comprehensive cost-study was performed in Colombia. The Argentinean study was the only attempt to conduct a cost-effectiveness analysis, but it only included medication costs, thereby offering a limited estimation.
The main limitations of this review include the high risk of bias of the included studies, mainly due to the possibility of under-reporting or selection bias and the heterogeneity of the information provided. Also, only studies published in 1990 and later were included; thus, the data on earlier treatments was unavailable for comparison.
This review addressed the research regarding the economics of MS and its treatments in LA. It also offered a platform to suggest directions for future research. We could address, as desirable future directions, some other endpoints: health-related QoL, health utility research (no data could be retrieved) and additional evidence on adherence and satisfaction with treatment.
Some evidence suggests that costs appear to be high; however, this is based only on two studies, one of which has a cost information source, which is unclear. Cost research should continue on a broader perspective, considering healthcare and societal costs. Economic efficiencies should be explored by targeting therapies to the most appropriate patients 12 . Finally, this type of SR should be updated as more evidence becomes available.
In summary, there is much to be learnt about MS costs in LA, particularly in relationship to the longitudinal course of severity of the disease. Future research performed in each country, considering the economic outcomes of MS, will expand the knowledge and management of MS in that particular region. There is also a need to develop guidelines to conduct studies on costs of illness in MS in order to improve their consistency, reliability and usefulness in decision making.
